What happened
- The FDA granted accelerated approval on 30 Oct 2026 to Voceryq for adults with recurrent respiratory papillomatosis, wart-like airway growths caused by HPV types 6 and 11.
- It delivers two DNA plasmids, one carrying HPV protein instructions and one an immune booster (IL‑12), into muscle cells using brief electrical pulses.
- In an open-label trial of 32 adults, 7 of 26 people who had needed at least three prior surgeries needed none in the year after treatment.
What we don't know yet
- Approval is based on fewer surgeries, an intermediate endpoint. Follow-up trials must confirm clinical benefit.
- There was no control group in the trial described.
Primary sources
- FDA press announcement, 30 Oct 2026Regulator decision
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.